Exabis Library
Welcome to the e-CCO Library!
OP019: Correlation of clinical and endoscopic outcomes in patients with active Crohn's disease treated with mongersen (GED-0301)
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
OP019: Correlation of clinical and endoscopic outcomes in patients with active Crohn’s Disease treated with mongersen (GED- 0301)
2017
ECCO'17 Barcelona
Wednesday, 15 March 2017, 2:34 PM by ECCO Administrator
1
OP019: Efficacy and safety of oral tofacitinib as induction therapy in patients with moderate-to-severe ulcerative colitis: results from 2 phase 3 randomised controlled trials
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
OP019: In Faecal Microbiota Transplantation (FMT) for Ulcerative Colitis, fusobacterium is associated with lack of remission, while metabolic shifts to starch degradation and short chain fatty acid production are associated with remission (FOCUS study)
2018
ECCO'18 Vienna
Friday, 23 March 2018, 12:23 PM
1
OP019: In faecal microbiota transplantation (FMT) for ulcerative colitis, fusobacterium is associated with lack of remission, while metabolic shifts to starch degradation and short-chain fatty acid production are associated with remission (FOCUS study)
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
OP01: Comparison of fecal transplantation, fecal transplantation with the novel UC diet or the UC diet alone for Refractory Mild to Moderate Active Ulcerative Colitis: The CRAFT UC randomized controlled trial
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
OP01: Comparison of fecal transplantation, fecal transplantation with the novel UC diet or the UC diet alone for Refractory Mild to Moderate Active Ulcerative Colitis: The CRAFT UC randomized controlled trial
2021
ECCO'21 Virtual
Friday, 1 October 2021, 12:41 PM
OP01: Higher versus standard adalimumab maintenance regimens in patients with Moderately to Severely Active Ulcerative Colitis: Results from the SERENE-UC maintenance study
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 5:40 PM
OP01: Higher versus standard adalimumab maintenance regimens in patients with Moderately to Severely Active Ulcerative Colitis: Results from the SERENE-UC maintenance study
2020
ECCO'20 Vienna
Tuesday, 23 June 2020, 4:58 PM
1
OP01: In-depth characterisation of host genetics and gut microbiome unravels novel host–microbiome interactions in inflammatory bowel disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
OP01: In-depth characterization of host-genetics and gut microbiome unravels novel host-microbiome interactions in Inflammatory Bowel Disease
2019
ECCO'19 Copenhagen
Tuesday, 28 May 2019, 3:32 PM
1
OP01: PROFILE: a multi-centre, randomised, open-label, biomarker-stratified clinical trial of treatment strategies for patients with newly-diagnosed Crohn’s disease
2024
ECCO'24 Stockholm
Tuesday, 30 April 2024, 5:03 PM
OP01: Sequencing-based gene network analysis reveals a profound role for ferroptosis key gene GPX4 in post-operative endoscopic recurrence in Crohn's disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
OP01: Sequencing-based gene network analysis reveals a profound role for ferroptosis key gene GPX4 in post-operative endoscopic recurrence in Crohn’s disease
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 2:22 PM
OP01: Withdrawal of infliximab or anti-metabolite therapy in Crohn’s Disease patients in sustained remission on combination therapy: A randomized unblinded controlled trial (SPARE)
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
OP02 Impact of therapeutic strategies on intestinal resection rate in paediatric inflammatory bowel diseases: A population-based cohort study over a 24-year period (1988–2011)
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
OP020: Filgotinib, a selective JAK1 inhibitor, induces clinical remission in patients with moderate-to-severe Crohn’s disease: interim analysis from the Phase 2 FITZROY study
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
OP020: Recent anti-TNF exposure predicts lower vedolizumab trough concentrations in patients with Crohn Disease
2017
ECCO'17 Barcelona
Wednesday, 15 March 2017, 2:33 PM by ECCO Administrator
1
OP020: Recent anti-TNF exposure predicts lower vedolizumab trough concentrations in patients with Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
OP020: The clinical determinants affect gut microbial profile of inflammatory bowel disease patients
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM